

IN THE CLAIMS:

Cancel claims 1-28 and 31-48. This leaves pending claims 29-30 and 49-69 as shown in the full listing of claims below.

Claims 1-28 (canceled)

1 Claim 29 (original): A layered tablet for the treatment of herpes simplex and
2 conditions giving rise thereto, said layered tablet comprising an immediate-release layer and
3 a sustained-release layer, and comprising the following as active ingredients distributed
4 between said immediate-release layer and said sustained-release layer in the following
5 approximate proportions expressed as relative weight percents:

	<u>Immediate-Release Layer</u>	<u>Sustained-Release Layer</u>
Magnesium L-ascorbate	40-60%	balance
2-Amino-2-deoxy-D-glucose	40-60%	balance
L-lysine monohydrochloride	40-60%	balance
N-acetyl-L-cysteine	40-60%	balance
Quercetin	40-60%	balance
L-Selenomethionine	100%	
Copper sulfate	100%	
Zinc picolinate	40-60%	balance

1 Claim 30 (original): A layered tablet for use as an oral dosage form, said
2 layered tablet comprising an immediate-release layer and a sustained-release layer, and
3 comprising the following as active ingredients distributed between said immediate-release
4 layer and said sustained-release layer in the following approximate proportions expressed as
5 relative weight percents:

	<u>Immediate-Release Layer</u>	<u>Sustained-Release Layer</u>
Magnesium taurate	40-60%	balance

L-selenomethionine	100%	
2-Amino-2-deoxy-D-glucose	40-60%	balance
L-Lysine ascorbate	50-60%	balance
Copper sulfate	100%	
Zinc lysinate	40-60%	balance
N-acetyl-L-cysteine	40-60%	balance
Quercetin	40-60%	balance

6 Claims 31-48 (canceled)

7 Claim 49 (original): A unit dosage form for the treatment of herpes simplex
8 and conditions giving rise thereto, said unit dosage form being a vaginal dosage form
9 selected from the group consisting of vaginally appropriate suppositories, creams, tablets and
10 gels, comprising as active ingredients:

- 11 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,
12 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,
13 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and
14 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 Claim 50 (original): A unit dosage form in accordance with claim 49 further
2 comprising as an active ingredient copper sulfate in a concentration ranging from about 0.4
3 µg/mL to about 15 µg/mL.

1 Claim 51 (original): A unit dosage form in accordance with claim 49 further
2 comprising as an active ingredient quercetin in a concentration ranging from about 0.12
3 µg/mL to about 2.75 µg/mL.

1 Claim 52 (original): A unit dosage form in accordance with claim 49 further
2 comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6
3 unit/mL to about 8 units/mL.

1 Claim 53 (original): A unit dosage form in accordance with claim 49 further
2 comprising as an active ingredient quercetin in a concentration ranging from about 0.12
3 µg/mL to about 2.75 µg/mL and heparin sodium in a concentration ranging from about 0.6
4 unit/mL to about 8 units/mL.

1 Claim 54 (original): A unit dosage form in accordance with claim 49 further
2 comprising as an active ingredient quercetin in a concentration ranging from about 0.12
3 µg/mL to about 2.75 µg/mL, heparin sodium in a concentration ranging from about 0.6
4 unit/mL to about 8 units/mL, and N-acetylcysteine in a concentration ranging from about 0.6
5 units/mL to about 8 units/mL.

1 Claim 55 (original): A unit dosage form for the treatment of herpes simplex
2 and conditions giving rise thereto, said unit dosage form being a mucosal dosage form
3 selected from the group consisting of vaginally appropriate suppositories, creams, tablets and
4 gels, comprising as active ingredients:

- 5 (a) ascorbic acid,
6 (b) 2-amino-2-deoxy-D-glucose,
7 (c) zinc sulfate, and
8 (d) L-lysine hydrochloride.

1 Claim 56 (original): A unit dosage form in accordance with claim 55 in which
2 the concentrations of said active ingredients are as follows:

- 3 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,
4 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,

- 5 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and
6 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 Claim 57 (original): A unit dosage form in accordance with claim 55 further
2 comprising as an active ingredient copper sulfate in a concentration ranging from about 0.4
3 µg/mL to about 15 µg/mL.

1 Claim 58 (original): A unit dosage form in accordance with claim 55 further
2 comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6
3 units/mL to about 8 units/mL.

1 Claim 59 (original): A unit dosage form in accordance with claim 55 further
2 comprising as active ingredients copper sulfate in a concentration ranging from about 0.4
3 µg/mL to about 15 µg/mL and heparin sodium in a concentration ranging from about 0.6
4 units/mL to about 8 units/mL.

1 Claim 60 (original): A unit dosage form in accordance with claim 55 further
2 comprising as an active ingredient N-acetyl-L-cysteine in a concentration ranging from about
3 0.02 mg/mL to about 0.5 mg/mL.

1 Claim 61 (original): A unit dosage form in accordance with claim 55 further
2 comprising as an active ingredient L-2-oxothiazolidine-4-carboxylate in a concentration
3 ranging from about 0.02 mg/mL to about 0.5 mg/mL.

1 Claim 62 (original): A unit dosage form for the treatment of herpes simplex
2 and conditions giving rise thereto, said unit dosage form being a topical dermal dosage form
3 selected from the group consisting of topical lotions, gels, creams, and emulsions, comprising
4 as active ingredients:

- 5 (a) ascorbic acid,
6 (b) 2-amino-2-deoxy-D-glucose,

- 7 (c) zinc sulfate, and
8 (d) L-lysine hydrochloride.

1 Claim 63 (original): A unit dosage form in accordance with claim 62 in which
2 the concentrations of said active ingredients are as follows:

- 3 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,
4 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,
5 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and
6 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 Claim 64 (original): A unit dosage form in accordance with claim 63 further
2 comprising as an active ingredient Cu^{+2} in a concentration ranging from about 0.15 µg/mL to
3 about 15 µg/mL.

1 Claim 65 (original): A unit dosage form in accordance with claim 64 further
2 comprising as an active ingredient quercetin in a concentration ranging from about 0.12
3 µg/mL to about 2.75 µg/mL.

1 Claim 66 (original): A unit dosage form in accordance with claim 65 further
2 comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6
3 unit/mL to about 8 units/mL.

1 Claim 67 (original): A unit dosage form in accordance with claim 66 further
2 comprising as an active ingredient D,α-tocopherol in a concentration ranging from about 16
3 µg/mL to about 1600 µg/mL.

1 Claim 68 (original): A unit dosage form in accordance with claim 67 in which
2 said D,α-tocopherol is in the form of D,α-tocopherol nicotinate in a concentration ranging
3 from about 19 µg/mL to about 2600 µg/mL.

- 1 Claim 69 (original): A unit dosage form in accordance with claim 67 in which
- 2 said D, α -tocopherol is in the form of D, α -tocopherol succinate in a concentration ranging
- 3 from about 19 $\mu\text{g/mL}$ to about 2500 $\mu\text{g/mL}$.